Kenya - English - Pharmacy and Poisons Board

bayer pharma ag bayer pharma ag 13342 berlin germany - sodium diatrizoate / meglumine diatrizoate - solution for injection - 1 ml urografin 76 % contains 0.1 g sodium… - contrast media - iodinated x-raycontrast media:

United States - English - NLM (National Library of Medicine)

slate run pharmaceuticals, llc - iopamidol (unii: jr13w81h44) (iopamidol - unii:jr13w81h44) - iopamidol injection is indicated for angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography), and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (cect) head and body imaging (see below). iopamidol injection may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. iopamidol injection may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. the usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. in calcified lesions, there is less likelihood of enhancement. following therapy, tumors may show decreased or no enhancement. the opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. iopamidol injection may be beneficial in the image enhancement of nonneoplastic lesions. cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. the use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. sites of active infection may also be enhanced following contrast media administration. arteriovenous malformations and aneurysms will show contrast enhancement. for these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. however, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. iopamidol injection may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. enhancement of computed tomography with iopamidol injection may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with ct alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). in other cases, the contrast agent may allow visualization of lesions not seen with ct alone (e.g., tumor extension), or may help to define suspicious lesions seen with unenhanced ct (e.g., pancreatic cyst). contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. therefore, utilization of a continuous scanning technique (“dynamic ct scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. for example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (ct number). a vascularized lesion is characterized by an increase in ct number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced ct findings. none.

India - English - Central Drugs Standard Control Organization

german r. - meglumine diatrizoate,iodine - vial - 0.65g(in aq. sol.),306mg;ml - 50ml

India - English - Central Drugs Standard Control Organization

german r. - diatrizic acid dihydrate eq. to diatrizic acid anhyd.,meglumine diatrizoate - inj - 493.19mg,156.81 - 20/50;ml

India - English - Central Drugs Standard Control Organization

dabur ph. - iodine,meglumine,sod.diatrizoate - inj % - 7.4g,159.24mg,597.3mg+water - 100ml v.

India - English - Central Drugs Standard Control Organization

dabur ph. - iodine,meglumine,sod.diatrizoate - inj % - 7.4g,159.24mg,597.3mg+water - 20/50 ml v.

India - English - Central Drugs Standard Control Organization

dabur ph. - iodine,meglumine,sod.diatrizoate - inj % - 5.84g,125.46mg,471.48mg+water - 20ml/50ml v.

India - English - Central Drugs Standard Control Organization

divine lab. - iodine,meglumine,sod.diatrizoate - inj - 20mlamp/50mlvial

Singapore - English - HSA (Health Sciences Authority)

transmedic pte ltd - ioversol - injection, solution - 741 mg/ml - ioversol 741 mg/ml

Singapore - English - HSA (Health Sciences Authority)

transmedic pte ltd - ioversol - injection, solution - 741 mg/ml - ioversol 741 mg/ml